Cantor Fitzgerald Comments on IDYA FY2026 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Cantor Fitzgerald issued their FY2026 earnings per share estimates for IDEAYA Biosciences in a report issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings of ($2.18) per share for the year. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the prior year, the business posted ($0.53) EPS.

Other equities research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. increased their price objective on shares of IDEAYA Biosciences from $63.00 to $66.00 and gave the company an “overweight” rating in a research note on Thursday, May 22nd. Stephens reaffirmed an “overweight” rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $54.27.

IDEAYA Biosciences Stock Up 4.2%

Shares of IDYA stock opened at $22.63 on Tuesday. The stock has a market cap of $1.98 billion, a P/E ratio of -6.86 and a beta of 0.04. IDEAYA Biosciences has a fifty-two week low of $13.45 and a fifty-two week high of $44.42. The business has a fifty day simple moving average of $18.50 and a 200-day simple moving average of $21.21.

Institutional Investors Weigh In On IDEAYA Biosciences

Institutional investors have recently bought and sold shares of the business. Rhumbline Advisers lifted its holdings in shares of IDEAYA Biosciences by 9.6% during the 1st quarter. Rhumbline Advisers now owns 124,437 shares of the company’s stock valued at $2,038,000 after acquiring an additional 10,876 shares in the last quarter. Millennium Management LLC raised its stake in shares of IDEAYA Biosciences by 345.2% during the first quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock valued at $8,970,000 after purchasing an additional 424,625 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of IDEAYA Biosciences by 8.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,044 shares of the company’s stock worth $938,000 after purchasing an additional 4,308 shares in the last quarter. MPM Bioimpact LLC lifted its position in shares of IDEAYA Biosciences by 3.9% during the first quarter. MPM Bioimpact LLC now owns 430,161 shares of the company’s stock worth $7,046,000 after purchasing an additional 16,126 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of IDEAYA Biosciences in the first quarter valued at $3,119,000. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.